Voyageur Pharmaceuticals (TSXV:VM) Cash-to-Debt : 6.25 (As of Feb. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Voyageur Pharmaceuticals's cash to debt ratio for the quarter that ended in Feb. 2024 was 6.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Voyageur Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Feb. 2024.

The historical rank and industry rank for Voyageur Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

TSXV:VM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 6.91 Max: No Debt
Current: 6.25

During the past 13 years, Voyageur Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 6.91.

TSXV:VM's Cash-to-Debt is ranked better than
72.72% of 1019 companies
in the Drug Manufacturers industry
Industry Median: 0.93 vs TSXV:VM: 6.25

Voyageur Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Voyageur Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Voyageur Pharmaceuticals Cash-to-Debt Chart

Voyageur Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Nov23

Cash-to-Debt

Get a 7-Day Free Trial

0.55

0.01

18.91

1.23

0.05

Voyageur Pharmaceuticals Quarterly Data
	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24
Cash-to-Debt	Get a 7-Day Free Trial															25.08	4.77	0.08	0.05	6.25

Competitive Comparison of Voyageur Pharmaceuticals's Cash-to-Debt

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals's Cash-to-Debt Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Cash-to-Debt falls into.

Voyageur Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Voyageur Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Nov. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.002	/	(0	+	0.04)
	=	0.05

Voyageur Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Feb. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	0.25	/	(0	+	0.04)
	=	6.25

Voyageur Pharmaceuticals (TSXV:VM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Voyageur Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Voyageur Pharmaceuticals (TSXV:VM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

VYYRF:USA

Address

333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1

Website

https://www.voyageurpharmaceuticals.ca

Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines